Sectoral Asset Management Inc. Acquires 958 Shares of United Therapeutics Corporation $UTHR

Sectoral Asset Management Inc. raised its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 125.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,723 shares of the biotechnology company’s stock after purchasing an additional 958 shares during the quarter. Sectoral Asset Management Inc.’s holdings in United Therapeutics were worth $840,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of UTHR. Darwin Global Management Ltd. bought a new position in United Therapeutics in the 3rd quarter valued at $317,617,000. Baillie Gifford & Co. bought a new position in United Therapeutics in the 4th quarter valued at $157,390,000. Balyasny Asset Management L.P. raised its position in United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after purchasing an additional 136,883 shares during the last quarter. Sofinnova Investments Inc. bought a new position in United Therapeutics in the 2nd quarter valued at $34,055,000. Finally, Orbimed Advisors LLC bought a new position in United Therapeutics in the 3rd quarter valued at $48,167,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,648,140.36. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nilda Mesa sold 258 shares of United Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total value of $150,137.94. Following the sale, the director directly owned 5,028 shares of the company’s stock, valued at approximately $2,925,944.04. This trade represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 555,473 shares of company stock valued at $310,786,074 in the last three months. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $568.43 on Monday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The business has a fifty day simple moving average of $563.25 and a 200 day simple moving average of $512.08. The stock has a market cap of $24.13 billion, a PE ratio of 20.98, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the firm earned $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Finally, Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.